Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990157 | 0.88 | EGFR (0.62) | EGFRRIPK2EPHB2KDRTEK | |
| SCHEMBL27482497 | 0.88 | KDR (0.68) | EGFRRIPK2EPHB2KDRTEK | |
| SCHEMBL29887853 | 0.86 | MAPT (0.48) | EGFRHTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL24569721 | 0.86 | MAPT (0.48) | EGFRHTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL2702250 | 0.86 | ERBB2 (0.66) | EGFRHTTLMNAMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL214923 | 0.85 | ERBB2 (0.64) | EGFRHTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL2511768 | 0.84 | EGFR (0.53) | EGFRRIPK2EPHB2KDRTEK | |
| Hydrochloric Acid SCHEMBL8809727 | 0.84 | KDR (0.70) | EGFRRIPK2EPHB2KDRTEK | |
| SCHEMBL18158544 | 0.83 | EGFR (0.77) | EGFRRIPK2EPHB2KDRERBB2 | |
| SCHEMBL29887945 | 0.83 | ERBB2 (0.47) | EGFRHTTLMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1182123-C | Substituted bicyclic derivatives useful as anticancer agents | �Ʒ� | 2004-12-29 | — | — | CN | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| CN-1333758-A | Substituted bicyclic derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | EGFR 265/4885RIPK2 4083/4885EPHB2 3693/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | EGFR 265/4885RIPK2 4083/4885EPHB2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.